BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, launched today with a $50 million Series A financing to usher in a new era of genetic medicines for a wide range of diseases. Kelonias platform overcomes the central challenge that has prevented the full realization of gene therapy for patients. Despite life-changing responses, existing gene therapies are highly complex, costly, and limited by complicated treatment paradigms, tractable therapeutic applications, and dose-limiting toxicities. By enabling precisely targeted, highly efficient, manufacturable off-the-shelf in vivo gene delivery, Kelonias technology has the potential to dramatically expand the impact and reach of genetic medicines to every patient in need.
Kelonia is backed by a strong syndicate of investors with a track record of successfully launching and building disruptive biotech companies. Alta Partners, Horizons Ventures, Venrock and other investors participated in the Series A round. The company will use the funding to redefine whats possible for genetic medicines starting with an off-the-shelf chimeric antigen receptor (CAR) to treat hematologic cancer that may enable the unrivalled clinical benefit of CAR T without the typical toxicities and with the ease of access of conventional medicines. Additionally, the company will advance other programs for oncology and non-oncology indications, and further expand its gene delivery platform and capabilities.
The cell and gene therapy field has been searching for solutions to durable in vivo genetic modifications regardless of whether applying gene editing, RNA expression or viral-mediated gene integration, said Kevin Friedman, Ph.D., President and Chief Scientific Officer of Kelonia. At Kelonia, we believe we have found an in vivo gene delivery solution that is safe, effective, and manufacturable for broad therapeutic application. With our Series A funding and key strategic collaborations, we will advance our lead product candidate toward clinical studies and further optimize our technology to explore treating diseases never thought possible with genetic medicines.
Based on discoveries made in the lab of Massachusetts Institute of Technologys Michael Birnbaum, Ph.D., and leveraging pioneering research from leading scientists at the French National Centre for Scientific Research (CNRS), Kelonias in vivo gene delivery technology enables a few potent lentiviral vector-like particles armed with an adjustable targeting system to precisely, efficiently, and safely deliver payloads exactly where needed to treat a broad range of diseases. The companys early applications combine oncology-targeted therapeutics, such as CAR and T cell receptor molecules, with Kelonias precision in vivo targeting technology. When used in concert, this combination enables potent and precise tumor targeting with limited off-tumor toxicity, which would otherwise be a concern. Administered directly in vivo as an off-the-shelf medicine, Kelonias transformational therapies in development for solid and hematologic tumors have the potential to democratize patient access to genetic medicines. Beyond oncology, the company will advance its technology to unlock delivery to previously hard-to-reach tissues, such as neurological, muscular or renal, to deliver different types of genetic cargo with the goal of radically transforming the treatment of diseases in these areas.
It turns out, a relatively simple and elegant idea to de-target and redirect lentivirus-like particles based on recently published research from my lab can potentially provide a solution to in vivo gene delivery, said Dr. Birnbaum, Ph.D., Co-Founder of Kelonia. Im incredibly excited about the potential of Kelonias platform and team to vastly expand the utility of gene therapies to treat oncology, autoimmune disease, rare monogenic or other diseases currently intractable to gene therapies.
Kelonia is combining the two crucial elements required to develop truly novel medicines: breakthrough biology and an exceptional team, said Bryan Roberts, Partner at Venrock. Michael Birnbaums industrially robust platform affords a targeting specificity log orders better than anything else out there and the team has a stellar track record for translating groundbreaking scientific gene therapy discoveries into viable products that are transformative for patients.
In addition to the completion of its Series A, Kelonia has established strategic collaborations with Adimab and ElevateBio. With both collaborations already successfully underway, each of these outstanding partners brings differentiating capabilities that enable and accelerate the companys vision to bring breakthrough genetic medicines to patients.
Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. Kelonia will leverage Adimabs expertise and proprietary technologies, across a range of applications, to access tissue-specific antibodies that enable unlocking precise in vivo gene delivery to different tissues as well as antibodies that can be leveraged within the therapeutic genetic cargo.
ElevateBio is a technology-driven company focused on powering transformative cell and gene therapies with multiple next-generation technology platforms and a fully integrated R&D and manufacturing facility. Through an expanding partnership, Kelonia will utilize ElevateBios lentiviral vector platform, process and analytical development expertise, and cGMP manufacturing capabilities to develop and advance novel manufacturing processes for Kelonia and manufacture of Kelonias products.
Leadership and Founding Team
Kelonia brings together industry leaders in cell and gene therapy responsible for the discovery and development of multiple clinical and commercial products including ABECMA, the first FDA-approved anti-BCMA CAR T cell therapy product for relapsed or refractory multiple myeloma. The companys leadership team includes Kevin Friedman, Ph.D., President and Chief Scientific Officer, Thomas Galbo, Ph.D., Chief Business Officer, and Molly Perkins, Ph.D., Vice President of Research.
Kelonias scientific founders include Michael Birnbaum, Ph.D., Associate Professor of Biological Engineering, Massachusetts Institute of Technology, and Michael Fischbach, Ph.D., Associate Professor of Bioengineering and of Medicine, Stanford University, both world-leading experts in the fields of microbiology, immunology, oncology, and cell and gene engineering.
The companys board of directors comprises Michael Birnbaum, Michael Fischbach, Kevin Friedman, Bryan Roberts and Bob More, Managing Director at Alta.
About Kelonia TherapeuticsKelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The companys simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need. Learn more about Kelonia at http://www.keloniatx.com and follow us on LinkedIn and Twitter.
- VA research will bring precision medicine to mental health - VAntage Point - VAntage Point Blog - June 11th, 2022
- Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and... - June 11th, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 11th, 2022
- UC develops new lung cancer treatment | University Of Cincinnati - University of Cincinnati - June 11th, 2022
- CTGT transactions: Beware of ripples in the safe harbor - JD Supra - June 11th, 2022
- Startup offers genetic testing that promises to predict healthiest embryo - WHYY - June 11th, 2022
- WHRY Funds Studies on Sex Differences in Treating Gastrointestinal Cancers, Bone Health in Transgender Youth, and the Greater Risk for Alzheimer's... - June 11th, 2022
- NIH awards USC more than $16 million for research on vascular dysfunction and Alzheimer's disease | Keck School of Medicine of USC - University of... - June 11th, 2022
- Effect of Metformin on Glycemic Control | DMSO - Dove Medical Press - June 11th, 2022
- Overcoming the Challenges of Cell and Gene Therapy Facilities - Genetic Engineering & Biotechnology News - June 3rd, 2022
- Organoids test gene therapies for Pitt-Hopkins syndrome - Spectrum - June 3rd, 2022
- Gene Therapy Successfully Treats Spinal Cord Injuries Without Side Effects - SciTechDaily - June 3rd, 2022
- The secret to a longer lifespan? Gene regulation holds a clue - EurekAlert - June 3rd, 2022
- Labcorp Expands Access to Comprehensive Genomic Testing Through New Lung Cancer Program - Business Wire - June 3rd, 2022
- Regenerative Medicine Market To Grow At A CAGR Of 11.27% By 2027, Due To Advancements In Cell Biology, Genomics Research, And Gene-Editing Technology... - June 3rd, 2022
- Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision... - June 3rd, 2022
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001 at the 2022 Annual European Hematology Association (EHA)... - June 3rd, 2022
- Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer - DocWire News - June 3rd, 2022
- Winship receives $11 million grant from the National Cancer Institute to improve immunotherapy for lung cancer - EurekAlert - June 3rd, 2022
- Gene Editing Service Market Report 2022-2028 | Keyplayers- Caribou Biosciences, CRISPR Therapeutics, Merck KGa, Editas Medicine The Greater... - June 3rd, 2022
- Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO -... - June 3rd, 2022
- The secret to a longer lifespan? Gene regulation holds a clue - University of Rochester - May 28th, 2022
- Welsh wins 2022 Shaw Prize in Life Sciences and Medicine | Carver College of Medicine - The University of Iowa - May 28th, 2022
- Episode 2: Are We Any Closer to Intestinal Gene Therapy in Crohn's Disease? - Medscape - May 28th, 2022
- Middle East Team Calls for Local Availability of Rapid WGS to Diagnose Severely Ill Infants - GenomeWeb - May 28th, 2022
- The Efficacy of Japanese Herbal Kampo Medicine as an Acute and Prophylactic Medication to Treat Chronic Daily Headache and Medication Overuse... - May 28th, 2022
- Breast cancer in man unexpectedly diagnosed after chest pain - The Columbus Dispatch - May 28th, 2022
- While the fetal clock develops, moms behaviour tells the time - The Daily Star - May 28th, 2022
- Foundation Medicine and Collaborators to Share More Than 20 Abstracts Featuring New Data at the 2022 American Society of Clinical Oncology Annual... - May 28th, 2022
- Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy - BioSpace - May 28th, 2022
- Project SG100K: DNA of 100000 Singaporeans to be mapped to identify new ways to prevent diseases - The Straits Times - May 28th, 2022
- Study reveals potential target for treatment of diseases associated with mitochondrial DNA mutations - EurekAlert - May 28th, 2022
- Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene... - May 28th, 2022
- INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual... - May 28th, 2022
- Outlook on the Single-use Technologies for Biopharmaceuticals Global Market to 2026 - Increasing Demand for Personalized Medicine is Driving Growth -... - May 28th, 2022
- Bostons Seaport gets new cell and gene therapy research center, more to come - Boston Herald - May 17th, 2022
- The CasPlus Gene Editing Platform Technology can Correct Mutations Associated with Duchenne's Muscular Dystrophy and Cystic Fibrosis with High... - May 17th, 2022
- Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene... - May 17th, 2022
- Will we be able to check cholesterol using gene editing technology or will it be too dangerous and costly to even try? - L'Observateur - L'Observateur - May 17th, 2022
- DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients - PR Newswire - May 17th, 2022
- Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics - GlobeNewswire - May 17th, 2022
- This Gene Mutation Breaks the Immune System. Why Has It Survived? - WIRED - May 17th, 2022
- BRCA Experts Rally to Research DNA Repair for Better Breast, Ovarian and Other Cancer Treatments - Yale School of Medicine - May 17th, 2022
- AskBio to Present 11 Abstracts at Upcoming American Society of Gene and Cell Therapy's 25th Annual Meeting - PR Newswire - May 17th, 2022
- Protein linked to intellectual disability has complex role Washington University School of Medicine in St. Louis - Washington University School of... - May 17th, 2022
- CU School of Medicine Research Defines the Role of HDAC6 in Regulating Heart Stiffness - University of Colorado Anschutz Medical Campus - May 17th, 2022
- Emendo Biotherapeutics' next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related... - May 17th, 2022
- Latest Human Cells Atlas reveals more of the unknown world inside our bodies - EL PAS in English - May 17th, 2022
- Middle-East precision medicine market was estimated to be at $3,942.6 million in 2021, which is expected to grow with a CAGR of 7.37% and reach... - May 17th, 2022
- CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting -... - May 6th, 2022
- Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American... - May 6th, 2022
- Top 12 emerging gene and cell therapy technologies likely to impact patient care announced in annual Disruptive Dozen from Mass General Brigham -... - May 6th, 2022
- Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results - GlobeNewswire - May 6th, 2022
- BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia... - May 6th, 2022
- Athenex, Texas Childrens Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for... - May 6th, 2022
- The gene-edited pig heart given to a dying patient was infected with a pig virus - MIT Technology Review - May 6th, 2022
- WMIF panel: How cell and gene therapy can overcome limitations of CAR T - MedCity News - May 6th, 2022
- Promising results shown in the treatment of growth-hormone resistant dwarfism - EurekAlert - May 6th, 2022
- New treatment for infants with weakened immune systems - Sciworthy - May 6th, 2022
- Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular... - May 6th, 2022
- Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases -... - May 6th, 2022
- A very specific kind of brain cell dies off in people with Parkinson's - Science News Magazine - May 6th, 2022
- Gene Editing Tools Market by 2029 Thermofisher Scientific, CRISPR Therapeutics, Editas Medicine Queen Anne and Mangolia News - Queen Anne and... - May 6th, 2022
- Sleep deprivation may increase the risk of eye disease - Medical News Today - May 6th, 2022
- Parkinson's Foundation Announces Major Expansion of PD GENEration Study, Increasing Access to Genetic Testing and Counseling Across the US - PR... - May 3rd, 2022
- Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease - Yahoo Finance - May 3rd, 2022
- Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy... - May 3rd, 2022
- Ting, Baric Elected to American Academy of Arts & Sciences | Newsroom - UNC Health and UNC School of Medicine - May 3rd, 2022
- Global Genes and the Orphan Disease Center of the University of Pennsylvania Host 7th Annual RARE Drug Development Symposium - Yahoo Finance - May 3rd, 2022
- May 2022: Nuclear condensates' role in gene regulation, disease focus of talk - Environmental Factor Newsletter - May 3rd, 2022
- Race, ethnicity, and ancestry have no standard definitions in medicine - Sciworthy - May 3rd, 2022
- Folk Medicine Discovery Could Lead to Better Heart Attack Outcomes - The Roanoke Star - May 3rd, 2022
- Genetic breakthrough could be the key that unlocks lupus - Cosmos - May 3rd, 2022
- ASGCT Partners with PlatformQ Health to Bring Impactful, Timely Gene and Cell Therapy Digital Education to Providers and Patients - PR Web - May 3rd, 2022
- Genomics technology and the future of food security and human health - TheCable - May 3rd, 2022
- Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting - GlobeNewswire - May 3rd, 2022
- ORYZON Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University - GlobeNewswire - May 3rd, 2022
- GAO Makes MACPAC Appointments and Reappointments | US GAO - Government Accountability Office - May 3rd, 2022
- Optogenetic Gene Therapy Company Ray Therapeutics Awarded $4 Million Grant - Pulse 2.0 - May 3rd, 2022
- Does autism begin in the womb? - EurekAlert - May 3rd, 2022